Traditional chemotherapy for treatment of relapsed/refractory Hodgkin lymphoma
| . | N . | ORR (%) . | CR (%) . | PFS . | OS . | Citation . |
|---|---|---|---|---|---|---|
| GDP | 23 | 69 | 17 | NR | NR | Baetz et al.11 |
| GVD* | 41 | 62 | 20 | 4-y EFS: 52% | 4-y OS: 70% | Bartlett et al.12 |
| ICE | 65 | 88 | 26 | 58% at 43 mo | NR | Moskowitz et al.13 |
| DHAP | 102 | 89 | 21 | NR | NR | Josting et al.14 |
| Nivolumab-ICE | 35 | 100 | 88 | 1 y: 90% | 1 y: 100% | Mei et al.15 |
| Pembrolizumab-GVD | 39 | 100 | 95 | 13.5 mo: 100% | 13.5 mo: 100% | Moskowitz et al.16 |
| BV-ICE | 45 | 91 | 74 | 2 y: 80.4% | 2 y: 97.8% | Lynch et al.17 |
| Gemcitabine | 23 | 39 | 9 | 6.7 mo | 10.7 mo | Santoro et al.19 |
| Vinblastine | 17 | 59 | 12 | 8.3 mo | 38.8 mo | Little et al.20 |
| Bendamustine | 35 | 53 | 33 | 5.2 mo | NR | Moskowitz et al.21 |
| . | N . | ORR (%) . | CR (%) . | PFS . | OS . | Citation . |
|---|---|---|---|---|---|---|
| GDP | 23 | 69 | 17 | NR | NR | Baetz et al.11 |
| GVD* | 41 | 62 | 20 | 4-y EFS: 52% | 4-y OS: 70% | Bartlett et al.12 |
| ICE | 65 | 88 | 26 | 58% at 43 mo | NR | Moskowitz et al.13 |
| DHAP | 102 | 89 | 21 | NR | NR | Josting et al.14 |
| Nivolumab-ICE | 35 | 100 | 88 | 1 y: 90% | 1 y: 100% | Mei et al.15 |
| Pembrolizumab-GVD | 39 | 100 | 95 | 13.5 mo: 100% | 13.5 mo: 100% | Moskowitz et al.16 |
| BV-ICE | 45 | 91 | 74 | 2 y: 80.4% | 2 y: 97.8% | Lynch et al.17 |
| Gemcitabine | 23 | 39 | 9 | 6.7 mo | 10.7 mo | Santoro et al.19 |
| Vinblastine | 17 | 59 | 12 | 8.3 mo | 38.8 mo | Little et al.20 |
| Bendamustine | 35 | 53 | 33 | 5.2 mo | NR | Moskowitz et al.21 |
Transplant-naive group only.
DHAP, dexamethasone, cytarabine, and cisplatin; EFS, event-free survival; GDP, gemcitabine, dexamethasone, and cisplatin; GVD, gemcitabine, vinorelbine, and liposomal doxorubicin; ICE, ifosfamide, carboplatin, and etoposide; NR, not reached; OS, overall survival.